NAT2 Gene Polymorphism in Bladder Cancer: A Study from North India

Abstract The relationship between smoking and bladder cancer risk and whether such effect is modified by the variation in NAT2 genotypes is investigated. This case control study was undertaken over a period of 19 months and included 106 bladder cancer patients and 110 controls. The NAT2 genotypes were identified by PCR-RFLP method in peripheral blood DNA samples. Genotype frequencies and the association of the genotypes among patients and controls group were assessed by c2 test and Fisher exact test. The NAT2 phenotypes were not significant in bladder cancer patients (OR=1.18, 95% CI: 0.69-2.03, P-value=0.583) alone or in combination with tobacco users (OR=0.84, 95% CI: 0.328-2.125, P-value=0.813) when compared with controls. These observations suggest that the NAT2 fast /or slow acetylators genotype is not associated with the risk of developing bladder cancer. Our data further demonstrated that bladder cancer patients who were tobacco users were not susceptible to the risk of developing bladder cancer as no significant association could be established.

[1]  N. Rothman,et al.  NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. , 2000, Pharmacogenetics.

[2]  J. Brockmöller,et al.  Arylamine N-acetyltransferase activity in man. , 1999, Drug metabolism reviews.

[3]  L. Kiemeney,et al.  Epidemiology of Bladder Cancer , 1999, European Urology.

[4]  H. Chiou,et al.  Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer , 1999, British Journal of Cancer.

[5]  T. Kawamoto,et al.  NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese , 1999, International journal of urology : official journal of the Japanese Urological Association.

[6]  Jack A. Taylor,et al.  The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. , 1998, Cancer research.

[7]  D. Grant,et al.  Human acetyltransferase polymorphisms. , 1997, Mutation research.

[8]  R. Bayoumi,et al.  Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. , 1997, Pharmacogenetics.

[9]  J. Brockmöller,et al.  Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. , 1996, Cancer research.

[10]  N. Caporaso,et al.  Cancer genes: single and susceptibility: exposing the difference. , 1995, Pharmacogenetics.

[11]  F. Guengerich.  Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. , 1995, The American journal of clinical nutrition.

[12]  B. Lin,et al.  Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. , 1994, Pharmacogenetics.

[13]  D. Grant,et al.  Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. , 1993, Carcinogenesis.

[14]  D. Hein.  Acetylator genotype and arylamine-induced carcinogenesis. , 1988, Biochimica et biophysica acta.

[15]  E. Miller.  Some current perspectives on chemical carcinogenesis in humans and experimental animals: Presidential Address. , 1978, Cancer research.

[16]  B. Ames,et al.  Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[17]  F. Kadlubar,et al.  Aromatic and heterocyclic amine metabolism and phenotyping in humans. , 1991, Progress in clinical and biological research.